Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial

Miranda Gogishvili, Tamar Melkadze, Tamta Makharadze, Davit Giorgadze, Mikhail Dvorkin, Konstantin Penkov, Konstantin Laktionov, Gia Nemsadze, Marina Nechaeva, Irina Rozhkova, Ewa Kalinka, Christian Gessner, Brizio Moreno-Jaime, Rodolfo Passalacqua, Siyu Li, Kristina McGuire, Manika Kaul, Anne Paccaly, Ruben G.W. Quek, Bo GaoFrank Seebach, David M. Weinreich, George D. Yancopoulos, Israel Lowy, Giuseppe Gullo, Petra Rietschel

Research output: Contribution to journalArticlepeer-review

100 Scopus citations

Fingerprint

Dive into the research topics of 'Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science

Keyphrases